Health Law Conference

• Kate Eshghi, Senior Vice President and General Counsel, UMass Memorial Healthcare
• Jamie Katz, General Counsel, Beth Israel Lahey Health
• Laura Peabody, Chief Legal Officer and General Counsel, Mass General Brigham
• Moderator: Deborah Devaux, Chair, Massachusetts Health Policy Commission

• Jeremy Meisinger, Senior Director, Federal Affairs, Blue Cross Blue Shield of Massachusetts
• Matt Selig, Executive Director, Health Law Advocates
• Sandra U. Wolitzky, Assistant Attorney General, Senior Health Policy Advisor, Health Care and Fair Competition Bureau, Massachusetts Attorney General’s Office
• Dianne Yacovone, Associate General Counsel, Office of the General Counsel, BMC Health System, Inc.
• Moderator: Toby Unger, Chief, Medicaid Fraud Division, Massachusetts Attorney General’s Office

In-house counsel at health care organizations of all sizes — from large integrated systems to community hospitals — and their outside counsel are facing an increasingly complex and fast-moving legal landscape. This session brings together leading practitioners to discuss the issues dominating boardrooms and compliance offices alike. Speakers will address the rapid rise of artificial intelligence and its implications for care delivery and research, the evolving regulatory framework around information blocking, and the latest DOJ enforcement priorities impacting the health care industry. Whether you are managing risk from the inside or advising clients from the outside, this session will offer practical insights and strategic guidance to help you stay ahead of the curve. 

• Emily M. Armstrong, Esq., Divisional Vice President, Deputy General Counsel for Metro Boston, Beth Israel Lahey Health
• Jehanne Bjornebye, Deputy General Counsel, Devoted Health
• Robert G. Martin, Deputy General Counsel, Mass General Brigham
• Lisa M. Re, Partner, Arnold & Porter LLP
• Moderator: Brian P. Dunphy, Partner, Arnold & Porter LLP

This panel will convene several area experts to discuss where the pharmacy industry is headed in 2026: covering the changing scope of pharmacist practice, the future of GLP-1 compounding, the evolution of PBM business models as states continue to restrict PBM control of pharmacies, and emerging state efforts to reshape the 340B program through contract pharmacy and transparency mandates.

• Karbert Ng, Director, Public Policy, Alnylam Pharmaceuticals
• Jeffrey W. Mittleman, Partner, Holland & Knight LLP

More speakers to be confirmed

• Patti Boozang, Senior Managing Director, Manatt, Phelps & Phillips, LLP
• Dan McHale, Senior Vice President, Healthcare Finance & Policy, Massachusetts Health & Hospital Association
• Kim Schellenberger, Chief Strategy Officer, Vinfen
• Dr. Monica Vohra, Chief Medical Officer, DotHouse 

More speakers to be confirmed